Total Payments
$78,061
2023 Payments
$465.00
Companies
4
Transactions
15
Medicare Patients
1,084
Medicare Billing
$241,051
Payment Breakdown by Category
Research$75,145 (96.3%)
Travel$2,329 (3.0%)
Food & Beverage$587.15 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75,145 | 11 | 96.3% |
| Travel and Lodging | $2,329 | 2 | 3.0% |
| Food and Beverage | $587.15 | 2 | 0.8% |
Payments by Type
Research
$75,145
11 transactions
General
$2,916
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $74,127 | 4 | $0 (2023) |
| F. Hoffmann-La Roche AG | $2,791 | 3 | $0 (2017) |
| Allergan Inc. | $1,018 | 7 | $0 (2018) |
| Genentech, Inc. | $125.15 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $465.00 | 1 | Eli Lilly and Company ($465.00) |
| 2022 | $1,619 | 1 | Eli Lilly and Company ($1,619) |
| 2021 | $72,043 | 2 | Eli Lilly and Company ($72,043) |
| 2018 | $1,144 | 8 | Allergan Inc. ($1,018) |
| 2017 | $2,791 | 3 | F. Hoffmann-La Roche AG ($2,791) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $465.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,619.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 06/29/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $66,478.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 03/17/2021 | Eli Lilly and Company | — | — | In-kind items and services | $5,564.59 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/25/2018 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $125.15 | General |
| 05/03/2018 | Allergan Inc. | — | — | In-kind items and services | $361.89 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/03/2018 | Allergan Inc. | — | — | In-kind items and services | $8.73 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/03/2018 | Allergan Inc. | — | — | In-kind items and services | $5.00 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/02/2018 | Allergan Inc. | — | — | In-kind items and services | $485.80 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/02/2018 | Allergan Inc. | — | — | In-kind items and services | $125.83 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/02/2018 | Allergan Inc. | — | — | In-kind items and services | $22.51 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 05/02/2018 | Allergan Inc. | — | — | In-kind items and services | $8.70 | Research |
| Study: Phase IIA US POP w SOD 3125-201-002 | ||||||
| 07/12/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $1,931.05 | General |
| Category: None | ||||||
| 07/12/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $462.00 | General |
| Category: None | ||||||
| 07/12/2017 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $398.00 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $73,662 | 3 |
| Phase IIA US POP w SOD 3125-201-002 | Allergan Inc. | $1,018 | 7 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $465.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 162 | 572 | $100,715 | $38,767 |
| 2022 | 3 | 188 | 777 | $132,228 | $45,597 |
| 2021 | 3 | 216 | 774 | $130,398 | $47,652 |
| 2020 | 6 | 518 | 2,161 | $319,875 | $109,035 |
Total Patients
1,084
Total Services
4,284
Medicare Billing
$241,051
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 437 | $67,451 | $25,980 | 38.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 48 | 54 | $18,711 | $7,057 | 37.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 44 | 50 | $7,718 | $2,957 | 38.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 31 | $6,836 | $2,773 | 40.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 648 | $100,019 | $33,856 | 33.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 59 | 64 | $22,176 | $8,287 | 37.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 61 | 65 | $10,033 | $3,454 | 34.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 78 | 612 | $90,950 | $32,238 | 35.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 71 | 84 | $27,902 | $11,308 | 40.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 67 | 78 | $11,547 | $4,106 | 35.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 150 | 1,072 | $156,222 | $59,343 | 38.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 95 | 762 | $91,675 | $22,546 | 24.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 76 | 99 | $32,310 | $10,540 | 32.6% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2020 | 62 | 70 | $15,750 | $6,798 | 43.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 98 | 117 | $16,743 | $6,445 | 38.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 37 | 41 | $7,175 | $3,362 | 46.9% |
About Dr. Gary Linker, MD
Dr. Gary Linker, MD is a Geriatric Psychiatry healthcare provider based in Fordland, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902856867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Linker, MD has received a total of $78,061 in payments from pharmaceutical and medical device companies, with $465.00 received in 2023. These payments were reported across 15 transactions from 4 companies. The most common payment nature is "" ($75,145).
As a Medicare-enrolled provider, Linker has provided services to 1,084 Medicare beneficiaries, totaling 4,284 services with total Medicare billing of $241,051. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Psychiatry
- Other Specialties Psychiatry
- Location Fordland, MO
- Active Since 05/11/2006
- Last Updated 04/17/2025
- Taxonomy Code 2084P0805X
- Entity Type Individual
- NPI Number 1902856867
Products in Payments
- Non-Covered Product (Drug) $2,791
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.